TOP > 外国特許検索 > METHOD FOR DETECTING NEUROLOGICAL DISEASE ACCOMPANIED BY INFLAMMATION AND/OR DEMYELINATION

METHOD FOR DETECTING NEUROLOGICAL DISEASE ACCOMPANIED BY INFLAMMATION AND/OR DEMYELINATION

Foreign code F140008052
File No. S2013-0209-C0
Posted date 2014年12月4日
Country 世界知的所有権機関(WIPO)
International application number 2013JP081385
International publication number WO 2014080979
Date of international filing 平成25年11月21日(2013.11.21)
Date of international publication 平成26年5月30日(2014.5.30)
Priority data
  • 特願2012-256701 (2012.11.22) JP
Title METHOD FOR DETECTING NEUROLOGICAL DISEASE ACCOMPANIED BY INFLAMMATION AND/OR DEMYELINATION
Abstract Disclosed is a novel means that is useful in establishing a diagnosis for a neurological disease accompanied by inflammation and/or demyelination, such as multiple sclerosis or neuromyelitis optica. The method provided by the present invention for detecting a neurological disease (excluding brain infarction) accompanied by inflammation and/or demyelination comprises assaying a protein Crtac1B in a sample separated from a subject and detecting the occurrence of the neurological disease depending on a low level of the Crtac1B protein mass.
Outline of related art and contending technology BACKGROUND ART
Multiple sclerosis (MS) as a marker for a definitive diagnosis, currently, oligoclonal banding included in the cerebral spinal fluid, cerebrospinal fluid or serum IgG and evaluating the quantitative changes in the index is used for IgG. However, rather than the specificity of these MS, in patients with clinically diagnosed with MS also negative cases and is not reduced, as well as a diagnostic marker of these does not reach a sufficient diagnosis (non-patent document 1). Once at the optic nerve has been included in the MS encephalomyelitis (NMO: is now recognized as a disease state to another) of the antibodies in the sera of patients with anti-aquaporin 4 antibody titer is high (non-patent document 2) can be present as a marker-associated, at the present time on the treated as another disease, or a negative antibody may be the meeting diagnostic criteria, the diagnostic antibody positive reason do not meet the criteria, additional diagnostic marker is determined that a complex diagnosis by strongly demanded. In addition to the above, multiple sclerosis, spinal cord nerve findings for the differential diagnosis of the flame is referred by the MRI. Further, meningitis, encephalitis and meningitis, encephalitis, encephalopathy is, the cerebrospinal fluid cells (monocytes, polynuclear ball or the like) is observed and the decrease in the amount of glucose (bacterial, tuberculosis property, such as fungal meningitis) is the major diagnostic criteria such as, poor laboratory finding of meningitis, encephalitis and meningitis, encephalitis, encephalopathy found in many, there is no diagnostic marker molecules.
On the other hand, multiple sclerosis, many of the optic nerve encephalomyelitis while repeating remission relapse after a definite diagnosis and progressed dysfunction, in part to the sustained activity is not subside follows a progression to a functional failure. Hyperreponsiveness acute recurrence or onset time of the activity of these assess the disease state, to perform the therapy and to quickly diagnose the disorder to prevent the progression of primary acute treatment is the same, as a method for evaluating MRI for these conditions generally used. However, MRI is limited and the test facility, an emergency facility even if there is a limited test facility can be enforced. In addition, other than the MRI examination, cerebrospinal fluid (MBP) myelin basic protein in the detection of recurrence is thought to be used in diagnosis of (non-patent document 3), resulting in a lack of specificity of the diagnostic does not occur. Meningitis diagnosis of the disease in an objective indicator is not present.
To Patent Document 1, a low value of the protein Crtac 1 in plasma as an indicator of the brain or cerebral infarct is a method of determining disease types that have been described. However, inflammation and demyelination such as multiple sclerosis and other neurological diseases associated with at least one of a method for definite diagnosis at an early stage has not been disclosed at all.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY
  • Inventor
  • TAKEI, Kohtaro
  • TAKAHASHI, Keita
  • SUZUKI, Yume
  • GOSHIMA, Yoshio
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close